A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension-Reference-Cited by-同舟云学术

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension

Published:2020-08-07 Issue:32 Volume:99 Page:e21465
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Wu Jiahui,Du Xin,Lv Qiang,Li Zhanquan,Zheng Zeqi,Xia Yong,Tang Chengchun,Yao Zhuhua,Zhang Jun,Long Mingzhi,Hisada Michie,Wu Jingtao,Zhou Wei,Ma Changsheng

Funder

Takeda Development Center Asia Pte Ltd.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference28 articles.

1. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Stanaway;Lancet,2018

2. Trends of hypertension prevalence, awareness, treatment and control in rural areas of northern China during 1991–2011;Wang;J Human Hypertens,2014

3. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey;Wang;Am J Hyperten,2014

4. Status of hypertension in China: results from the China hypertension survey, 2012–2015;Wang;Circulation,2018

5. Health system strengthening and hypertension awareness, treatment and control: data from the China health and retirement longitudinal study;Feng;Bull World Health Organ,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2024-07-04

2. Changing Concepts About Optimal Target Blood Pressure and the Therapeutic Advantages of Azilsartan for Achieving it;Kardiologiia;2024-04-30

3. Effect of Azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis;Annals of Medicine & Surgery;2023-12-11

4. Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review;Terapevticheskii arkhiv;2023-11-03

5. Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan;International Journal of Hypertension;2022-03-19